

Management of Prostate ailments through Homoeopathy

Dr. Tridibesh Tripathy

Subject Expert, Master of Public Health (Community Medicine) Course, Department of Social Work, Lucknow university, Lucknow, Uttar Pradesh, India

Abstract

As males become older, one obviously becomes aware of his prostate. The current case study deals with the ailments of the prostate. Here it specifically deals with one indicator related to the cancer of the prostate. The Prostate Specific Antigen (PSA) is the issue dealt here through the case. Usually, the threshold level of PSA in the serum is 4 ng/ml as patients with PSA lower than 4 ng/ml are considered negative for malignancy in absence of biopsy.

The said case was treated when the serum had high PSA with multiple Homoeopathic medicines. In two-months treatment period, the PSA level in the serum reduced drastically. Constitutionally, Lycopodium was prescribed based on generalities along with specific medicines like Scrophularia Nodosa-Q, Sabal Serrulata-Q, Ferrum Pic-3x and Ferrum Iod-3X were prescribed to reduce the swelling and hypertrophy of the prostate gland. Carcinosis-200 was also prescribed as a nosode as PSA is linked to prostate cancer. The details of the treatment regime are discussed in detail in the case. The case was asymptomatic after 6 months of treatment period.

Keywords: PSA, prostate, biopsy, threshold level, generalities, constitutional medicine, BHP

Introduction

Prostate cancer is the second most common cancer and the 5th leading cause of cancer associated mortality among men world wide^[1]. Screening for prostate cancer with serum PSA aims to detect prostate cancer at an early, intervenable stage amenable to curative treatment and reduction in overall disease specific mortality^[2,3]. PSA screening leads to increased prostate cancer diagnosis^[4,5]. Although clinically recommended, screening of PSA remains controversial^[4,5]. Further, no evidence has so far demonstrated that screening for prostate cancer saves lives^[4,5]. Another study adds that screening for prostate cancer may result in a small absolute benefit in disease specific mortality over 10 years but does not improve overall mortality^[6]. The study further adds that these benefits need to be weighed against the potential short- and long-term harms of PSA screening including, complications from biopsies and subsequent treatment & the risk of overdiagnosis and treatment^[6].

Incidence for prostate cancer in western population is greater than in Indians^[1]. Screening with PSA has resulted in stage and age migration there by facilitating detection of prostate cancer at an earlier stage^[2]. PSA is not a diagnostic test and it is only a first step towards taking a decision for biopsy. With a very low specificity, there is an inherent risk of doing unnecessary biopsy at the threshold of 4ng/ml². A cut off for biopsy in symptomatic men with negative Digital Rectal Examination (DRE) could safely be raised to 5.4ng/ml which could avoid subjecting 10% of men to undergo unnecessary biopsy^[7].

It is a known fact that with increase in serum PSA levels, its positive predictive value to detect cancer also increases. The term cancer detection rate is often used incorrectly as the denominator is taken as number of patients who are

screened for PSA and not the ones who are biopsied. There could be an impact of verification bias because to derive test characteristics, patients with PSA less than 4 ng/ml are considered negative for malignancy in absence of biopsy^[8]. High fat dairy, particularly whole milk, in healthy men may increase the risk of aggressive prostate cancer⁹. Whole milk consumption after prostate cancer diagnosis is associated with increased risk of recurrence, particularly among very overweight or obese men. Men with prostate cancer who choose to drink milk should select non fat or low fat options^[9].

Discussion of the case report

Male, aged 80 years developed weakness in both the legs and complained of dragging the legs while walking for the last 7 days in first week of April 2019. Based upon the acuteness of symptoms and the generalities Lycopodium-1M was prescribed and 7 doses of the medicine were given with once a day dosage. There was aggravation from motion, cold and better by warmth application. The generalities were thirst-less ness and craving for sweets. As specific medicines, Lathyrus Sativus-200/30ml was also given with four doses daily where the patient was asked to take 20 drops in half cup of room temperature water. By 7 days, Lycopodium medication was over but Lathyrus was continued for 12 days in all till the 30 ml finished. There was no improvement after 12 days.

The case was referred to an allopathic doctor having MD (medicine) degree. The doctor asked for a MRI of the brain and after the MRI reports, provisionally diagnosed the case as a cerebral atrophy (Fig 1) and also did basic pathological investigations (Fig 2) and prescribed medicines for a week. There was no improvement. During this time, no homoeopathic medicine was given.




Fig 1




Fig 2

The case was referred to a neurologist who provisionally diagnosed the case as Tuberculosis of spine but the PCR

report did not confirm tuberculosis (Fig 3).




Fig 3

Meanwhile, 4 doses of Conium-1M was prescribed to the patient with one dose daily for 4 days. The prescription was based on old age and paralysis of lower extremities. There was no improvement. Thereafter, the case was referred to an orthopaedic surgeon who did the PET-CT scan and found the case to be metastatic

prostatic carcinoma in the first week of May 2019 and operated on the metastatic spine of the case while getting the PSA test also done in the first week of May 2019. The PSA level showed 595.800 ng/ml (Fig 4). Fig 5,6,7 shows the PET-CT scan of the case.





Fig 4

PET-CT REPORT



UTKAL
UNIVERSITY OF BIOMEDICAL SCIENCES
HOSPITAL
Largest Ho

Name: <u>[Redacted]</u>		NM ID: PET/MAY/02/07/19
Sex: Male	Age: 80 Years	UH No: 2019001936
Referring Physician: Dr. Sandeep Biswal.		Date: 02.05.2019

Clinical History and Indication: Case of suspected unknown primary malignancy for evaluation.

PROCEDURES/ACQUISITION PROTOCOL

Scanner: GE Optima 560 PET-CT
Radioisotope: 18 F FDG (7 mCi)/60 minutes uptake period
Study Mode: PET-3D mode, Ultra HD & CT: 140 Kv in auto mA Mode, motion free acquisition.
Extent of Study: Vertex of the Skull to mid thighs
Special acquisition: HRCT Chest
Contrast: Oral and Intra venous contrast was given.
Semiquantitative analysis of FDG activity: Calculated as SUV BW g/ml.
Blood glucose level: 112 mg/dl.
Serum Creatinine: 1.3 mg/dl.

FINDINGS


- Biodistribution of the FDG appears to be within normal limits.
- Age related cortical atrophic changes are seen. Brain parenchyma appears normal. No abnormal increased / reduced tracer activity, abnormal contrast enhancement or space occupying/mass lesion seen in the brain parenchyma. (Note: All brain metastases may not be apparent on PET – CT scan and MR imaging may be performed where clinically indicated).
- No evidence of abnormal hypermetabolic cervical or supraclavicular lymph nodes.
- No evidence of any focal abnormal FDG uptake or lesion in oropharynx/nasopharynx/hypopharynx. Physiological FDG uptake is seen in bilateral sternocleidomastoid and longus coli muscles.
- Thyroid gland appears unremarkable.

1 | Page

UTKAL HEALTHCARE PRIVATE LIMITED
 Plot No.- C/3, Niladri Vihar, CS pur, Bhubaneswar-21, Mob.: 6370704001 / 02, www.uims.in

Fig 5

PET-CT REPORT



UTKAL
UNIVERSITY OF BIOMEDICAL SCIENCES
HOSPITAL

Name: <u>[Redacted]</u>		NM ID: PET/MAY/02/07/19
Sex: Male	Age: 80 Years	UH No: 2019001936
Referring Physician: Dr. Sandeep Biswal.		Date: 02.05.2019

- No focal abnormal FDG uptake or soft tissue density nodules seen in the bilateral lungs. No evidence of pleural effusion is seen. No abnormal hypermetabolic mediastinal or axillary lymph nodes are seen.
- Stomach, GE junction and esophagus appear unremarkable.
- Liver appears normal in size. There is no evidence of focal abnormal FDG uptake or hypodense lesions. Gall bladder and biliary tree appears normal. No evidence of IHBR or portal vein dilatation seen. The pancreas appears normal. Bilateral adrenal glands appear unremarkable with no focal abnormal FDG uptake. Spleen appears unremarkable with no abnormal FDG uptake. No free fluid is seen in the abdomen and pelvis.
- No evidence of abnormal hypermetabolic abdominal / retroperitoneal / inguinal lymph nodes seen.
- Bilateral kidneys appear normal in shape and location with no evidence of focal abnormal FDG uptake is seen. No evidence of hydroureteronephrosis or calculi found. Urinary bladder appears to be normal.
- Prostate gland appears enlarged in (size 4.8 x 4.6 x 5.7 cm). Mild FDG uptake is seen in enhancing area in the left peripheral zone of entire prostate gland involving postero lateral aspect of urinary bladder (SUVmax 3.24). Physiological tracer uptake is seen in the bilateral testicles.
- Increased FDG uptake is seen in lytic sclerotic lesions in following bones:
 - Ramus of mandible on right side (SUVmax 4.9).
 - Few vertebrae – D1, D8, D11, D12, L3, L4 (SUVmax 7.47 with intraspinal extension), sacrum (SUVmax 4.78).
 - Right ischiopubic ramus (SUVmax 4.9).
 - Right proximal humerus (SUVmax 6.06).

2 | Page

UTKAL HEALTHCARE PRIVATE LIMITED
 Plot No.- C/3, Niladri Vihar, CS pur, Bhubaneswar-21, Mob.: 6370704001 / 02, www.uims.in

Fig 6




Fig 7

Thereafter, the doctor also did the biopsy of the tumours of the spine and the vertebral body mass and the report suggested Renal carcinoma (Fig 8).




Fig 8

The patient was discharged with medications for post-surgery period for recovery. The course of Allopathic medicines lasted for 7 days. Meanwhile, along with these medicines, Homoeopathic medicines were also prescribed for the prostate to reduce the serum PSA level. The treatment started from 4th May 2019.

The medicines prescribed were Lycopodium- 1M based on generalities as already mentioned above with daily one dose for 15 days. The other specific medicines were Scrophularia Nodosa-Q, Sabal Serrulata-Q, Ferrum Pic-3x and Ferrum Iod-3X were prescribed to reduce the swelling and

hypertrophy of the prostate gland. Carcinoin-200 was also prescribed as a nosode as PSA is linked to prostate cancer^{4,5}. The dosage of all these medicines were 20 drops 4 times daily in half cup of room temperature water. After 15 days, Lycopodium was discontinued. Carcinoin was given for 15 days also i.e. till the 30 ml bottle lasted. Rest medicines were continued with the same dosage till the first week of July 2019.

On 1st July 2019, the PSA report showed 2.740ng/ml which reflects that the level is now in the normal range (Fig 9).




Fig 9

Further Immuno Histo Chemistry (IHC) tests were done on 2nd July 2019 to confirm prostate carcinoma and the report

confirmed the case as metastatic acinar prostate adenocarcinoma (Fig 10).

Financial support and sponsorship

Nil

Conflict of interest

Nil

References

1. International agency for research on cancer, GLOBOCAN, 2012, cancer incidence and mortality world-wide in 2012.
2. Lin K, et.al, U.S. preventive services task force, benefits and harms of PSA screening for cancer, an evidence update for the U.S. preventive services task force, *Ann Intern Med*, 2008, PMID: 18678846.
3. Vickers AJ, Prostate Cancer Screening, time to question how to optimize the ratio of benefits & harms, *Ann Intern Med*, 2017, PMID:28869975.
4. Djulbegovic M, et.al, Screening for prostate cancer, systematic review and meta-analysis of randomized controlled trials, *BMJ*, 2010, PMID:20843937.
5. Illic D, et.al, Screening for prostate cancer, *Cochrane database systematic review*, 2013, PMID:23440794.
6. Illic D, et.al, Prostate cancer screening with PSA test, a systematic review & meta-analysis, *BMJ*, 2018, 362, K 3519.
7. Shalini A, et.al, Raising cut off value of PSA for biopsy in symptomatic men in India to reduce unnecessary biopsy, *IJMR*. 2014; 139(6):851-856.
8. Punglia RS, et.al, effect of verification bias on screening for prostate cancer by measurement of PSA, *N.Engl J Med*. 2003; 349:335-42.
9. David Tat BS, et.al, Milk & other dairy foods in relation to prostate cancer recurrence, data from the cancer of the prostate strategic urologic research endeavour, *HHS Public Access, Prostate*. 2018; 78(1):32-39.
10. Boericke William. *New Manual of Homoeopathic Materia Medica with Repertory*, reprint edition, 2008, B. Jain publishers private limited, New Delhi, pages- 362-366, ISBN- 978-81-319-0184-7.